Context Therapeutics Inc. (CNTX)
CNTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CNTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001842952 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued." | 10-Q 2026-11-10 |
| Cash and burn | $34.4M cash; operating cash flow -$8.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 91,879,177 (2026-11-06); 91,879,177 a year earlier; 15,966,053 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-07-31 |
| Auditor | CohnReznick LLP, Parsippany, New Jersey, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$7.6M | -$6.6M | $34.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$14.6M | -$7.0M | $43.0M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$8.7M | -$11.4M | $54.5M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$13.0M | -$8.9M | $66.0M | No debt tags | Needs four quarters | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | Not filed | -$9.7M | -$6.6M | $76.9M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$8.8M | -$5.8M | $83.5M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$4.6M | -$5.0M | $89.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$3.3M | -$4.9M | $94.4M | No debt tags | Needs four quarters | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-10-24 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 309 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.7% |
| 1 month | -34.2% |
| 3 months | -64.2% |
| Year to date | -87.7% |
| 1 year | -84.3% |
| From 52-week high | -94.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
| PBM | Psyence Biomedical Ltd. Common Shares | $2.83 | -11.56% | $15.0M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| NCEL | NewcelX Ltd. | $2.75 | +5.36% | $15.9M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier